Six details:
1. Dr. Vizesi will continue to lead the development of SeaSpine’s orthobiologics portfolio and work with leaders of the spinal implant and enabling technology business to drive research across all product lines, according to a March 7 news release.
2. Under Dr. Vizesi’s leadership, SeaSpine deepened its research to differentiate its demineralized bone matrix portfolio. The company now holds the No. 2 position in the U.S. DBM market, according to Keith Valentine, president and CEO.
3. Research on SeaSpine’s DBM products has been published in peer-reviewed journals, including The Journal of Bone & Joint Surgery.
4. SeaSpine also promoted Shaeffer Bannigan to vice president of product development for spinal implants.
5. Since 2018, when Mr. Brannigan joined SeaSpine, he has helped execute more than 45 product launches.
6. More than 75 percent of SeaSpine’s spinal implants revenue comes from products launched within the last five years, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.